Exact Sciences Corp. (Nasdaq: EXAS) reported that its Cologuard colorectal cancer screening test met the goal of a late stage trial but the detection rate fell short of analyst expectations. Shares of the molecular diagnostics company plummeted $2.38 to $7.61.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here